U.S. markets closed

Bionomics Limited (BNOEF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.02370.0000 (0.00%)
At close: 12:38PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0237
BidN/A x N/A
AskN/A x N/A
Day's Range0.0237 - 0.0237
52 Week Range0.0130 - 0.0700
Avg. Volume43,141
Market Cap32.142M
Beta (5Y Monthly)2.37
PE Ratio (TTM)N/A
EPS (TTM)-0.0120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BNOEF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • GlobeNewswire

    Quarterly Activities and Cashflow Report

    ADELAIDE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 31 December 2022 (Quarter) and up to the da

  • Benzinga

    All Focus Shifts To Bionomics' PTSD Study After Anxiety Trial Disappoints

    Bionomics Limited (NASDAQ: BNOX) announced results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety Disorder (SAD), showing a miss on the primary endpoint. HC Wainwright, while downgrading the stock to Neutral from Buy, discussed the history of BNC210 and the PTSD program previously. The analyst writes that it has received baseline support from models of conditioned fear extinction and clinical effect from enhanced emotional recovery from CCK-induced panic attacks

  • Benzinga

    Bionomics' Social Anxiety Disorder Study Fails To Meet Primary Endpoint

    Bionomics Limited (NASDAQ: BNOX) announced results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety Disorder (SAD). The trial enrolled 151 adult patients. The primary endpoint, measured by the change from baseline to the average of the Subjective Units of Distress Scale (SUDS) scores during a 5-minute Public Speaking Challenge, was not met in the BNC210-treated patients when compared to placebo. SUDS is a tool for quantifying the intensity of anxiety, fear, or dis